Empfohlen
Empfohlen
Weitere ähnliche Inhalte
Was ist angesagt?
Was ist angesagt? (20)
Andere mochten auch
Andere mochten auch (20)
Ähnlich wie Amgen Presentation at VBHC Prize 2015 event
Ähnlich wie Amgen Presentation at VBHC Prize 2015 event (20)
Kürzlich hochgeladen
Kürzlich hochgeladen (20)
Amgen Presentation at VBHC Prize 2015 event
- 1. Patients first patient experiences & collaboration Joep Rijnierse Medical Director Amgen Netherlands AMG-NLD-AMG-171-2015-April-P
- 2. Amgen is the first and largest biotech company, developing medicine for patients with high unmet medical need • Established in 1980, with headquarters in Thousand Oaks, California • Innovative R&D and innovative production sites, best in class • Approx. 18.000 employees worldwide • Active in the US and 46 countries worldwide “Amgen is determined to unlock the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics”
- 3. With 12 products in 4 TA’s and a pipeline of 6 products in 2 additional TA’s, Amgen continues to serve patients
- 4. Amgen’s mission is to serve patients Aspiration Dutch affiliate: Amgen reliably provides best-in-class innovative and established (bio)pharmaceutical solutions for serious diseases and works closely with healthcare professionals, insurers and government agencies, to create significant value for patients both now and in the future. X-functional teamwork * entrepreneurship * compliance
- 5. 7For Internal Use Only. Amgen Confidential. Amgen’s Strategic Priorities are centred around delivering of patient value Deliver outstanding performance DEFEND / GROW Engage and shape the environment Deliver patient value Drive successful launches Engaged and high performing organization TRANSFORM TRANSFORM LAUNCH / ADVANCE TRANSFORM
- 6. Overall objective of VBHC @ Amgen is to fundamentally change the way we operate in the Health Care Landscape Amgen’s collaborates with stakeholders in care market • Development of innovative biotech drugs • In depth knowledge of Dutch healthcare system and understanding of future trends • Knowledge of concept of Value Based Health Care • Network of consultants to develop best value proposition per individual project • Willingness to collaborate with all care stakeholders Health Care Provider Health Insurer Patient / Insured Care Insurance Market Care Buying Market Care Provider Market Dutch Health Care Market consists of 3 major players
- 7. Amgen solidly anchors VBHC in the Dutch organisation trough instalment of a VBHC Center of Excellence VBHC Center of Excellence has 3 focus areas: 1. Support Amgen's in-line portfolio • Develop innovative collaboration pilots to add value for players in health care market 2. Create Access for Amgen's pipeline portfolio • Develop innovative collaboration pilots to add value for players in health care market 3. Be a Center of Excellence • Organise training on VBHC Amgen staff • Engage with relevant consultants and develop network for future collaboration
- 8. 6 pilots in collaboration with stakeholders in health care market & consultants Value Chain Analysis • Outpatient pharmacists • Best practice sharing • Blue Print of ideal value chain • Patient service & Cost Containment Patient Flow Analysis • Big Academic Center • Patient flow for MM • Optimize patient flow • Patient service & Cost Containment Patient Flow Analysis • Big Nephrology Center • Patient flow for Dialysis patient • Optimize patient flow • Patient service & Cost Containment Home Infusion • Oncology centres • Added value of home set-up vs hospital set-up? • Patient service & Cost Containment Patient Outcome measures • Big peripheral haematology Center • In close collaboration with patient association • Map out relevant patient measures for optimal ITP treatment • Develop optimal patient flow with relevant outcome measures Patient Outcome Measures • Big Nephrology Center • Patient measures for dialysis • Measure quality A
Hinweis der Redaktion
- We have 12 medicines on the market today (US)… EPOGEN First Blockbuster Treats lower than normal number of red blood cells (anemia) caused by chronic kidney disease in patients on dialysis. Acts like the hormone erythropoietin. It helps the body create more red blood cells, which raises the hemoglobin (Hb) level. Prescribed for more than 20 years NEUPOGEN: Used to reduce the risk of infection in patients with some tumors receiving strong chemotherapy that may cause severe neutropenia (nu-tro-peen-ee-ah) with fever. Neutropenia is when the body makes too few neutrophils (nu-tro-fils), a type of white blood cell that helps fight infection. G-CSF (granulocyte colony-stimulating factor) is a substance naturally produced by the body that stimulates the growth of neutrophils. NEUPOGEN is a man-made form of G-CSF made using the bacteria Escherichia coli. ARANESP: Similar to EPO but longer lasting than EPO. Approved for treatment of anemia in patients with chronic kidney disease (not just dialysis as with EPO) or anemia caused by chemotherapy that will be used for at least two months after starting Aranesp NEULASTA: Similar to Neupogen, but longer lasting. ENBREL: Used to treat multiple long-term inflammatory diseases including moderate to severe rheumatoid arthritis (RA) Tumor necrosis factor (TNF) is a substance made by your body's immune system. People with inflammatory diseases like rheumatoid arthritis have too much TNF in their bodies. ENBREL reduces levels of the active form of TNF. SENSIPAR / MIMPARA Indicated for the treatment of secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) on dialysis. Sold by Amgen under the trade name Sensipar in North America and Australia and as Mimpara in Europe. One of the few small molecule (pill) medicines sold by Amgen It works on parathyroid glands to release less calcium and phosphorus into bones. VECTIBIX Indicated for the treatment of patients with certain types of colorectal cancer Targets the epidermal growth factor receptor (EGFR), a protein that plays an important role in cancer cell signaling. It binds to the EGFR receptor, interfering with the signals that might otherwise stimulate growth and survival of the cancer cell. NPLATE: Indicated for treatment of thrombocytopenia in patients with chronic immune thrombocytopenia (ITP) in certain instances. Nplate is a peptibody protein, a novel platform developed by scientists at Amgen. A peptibody is an engineered protein, made by recombinant DNA technology, with attributes of both peptides and antibodies. Designed to bind to the thrombopoeitin (TPO) receptor thereby stimulating platelet production. PROLIA: Used to treat osteoporosis in women after menopause at high risk for fracture. It helps stop the development of bone-removing cells (osteoclasts) before they can reach and damage the bone. Prolia inhibits RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors. XGEVA: Indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors. Like Prolia, inhbits RANKL from activating its receptor, RANK on the surface of osteoclasts, thereby decreasing bone destruction. KYPROLIS Developed and marketed by Onyx Pharmaceuticals (except in Japan), an Amgen subsidiary Approved for the treatment of patients with multiple myeloma who have already received at least two other treatments As a proteasome inhibitor, it blocks the action of proteasomes, cellular complexes that break down proteins NEXAVAR Indicated for a certain type of thyroid cancer, and certain types of kidney and liver cancer. Developed and marketed under collaboration and co-promotion agreements between Bayer Healthcare and Onyx Pharmaceuticals May interfere with tumor cell signals or decrease the formation of new blood vessels that provide oxygen and nutrients to cancer cells. Small molecule (pill) ALL OF OUR PRODUCTS HAVE SERIOUS RISKS AND SOME PRODUCTS MAY HAVE LIFE-THREATENING RISKS. FOR MORE COMPLETE INFORMATION ABOUT OUR PRODUCTS AND RISK INFORMATION, PLEASE SEE THE PRODUCT WEBSITE. PLEASE NOTE THAT THIS IS A GENERAL OVERVIEW AND DOES NOT INCLUDE EVERY INDICATION FOR EVERY PRODUCT